Structure Therapeutics Inc. Sponsored ADR $GPCR is Catalio Capital Management LP’s 10th Largest Position

Catalio Capital Management LP decreased its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 61.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 252,901 shares of the company’s stock after selling 398,909 shares during the quarter. Structure Therapeutics makes up about 3.3% of Catalio Capital Management LP’s holdings, making the stock its 10th biggest position. Catalio Capital Management LP owned approximately 0.42% of Structure Therapeutics worth $17,589,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of GPCR. State of Wyoming bought a new position in shares of Structure Therapeutics during the 2nd quarter valued at $28,000. EverSource Wealth Advisors LLC raised its holdings in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares in the last quarter. CWM LLC raised its holdings in shares of Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Structure Therapeutics during the 4th quarter valued at $127,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $45.00 on Thursday. The firm has a market capitalization of $3.20 billion, a price-to-earnings ratio of -51.72 and a beta of -1.35. The company’s fifty day moving average is $43.09 and its two-hundred day moving average is $57.53. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $15.80 and a 52-week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Citizens Jmp cut their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the company an “outperform” rating in a report on Tuesday, March 17th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Finally, Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.